Second Malignancy

Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.

September is Childhood Cancer Awareness Month.

Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.

Most childhood cancer survivors are not up to date on guideline-recommended screening for late effects of cancer treatment or second malignancies, according to study results.